# Atrial myocyte senescence as a driver of atrial fibrillation: mechanisms and therapeutic implications

**Authors:** Zhaoyang Wei, Zhixiong Li, Nanhu Quan

PMC · DOI: 10.3389/fcell.2025.1702207 · Frontiers in Cell and Developmental Biology · 2026-01-14

## TL;DR

This review explains how aging of heart cells contributes to atrial fibrillation and suggests new treatment targets.

## Contribution

The paper introduces an integrated 'senescence–AF axis' model linking cell aging to atrial fibrillation and identifies novel therapeutic targets.

## Key findings

- Atrial myocyte senescence contributes to atrial fibrillation through inflammation, calcium dysregulation, and cell cycle disruption.
- Epigenetic changes and SIRT1/mTOR signaling dysregulation are key drivers of electrical and structural heart remodeling.
- Potential therapies include SIRT1 activators and NLRP3 inhibitors to target senescence-related pathways.

## Abstract

Atrial fibrillation (AF) is the most common type of arrhythmia encountered in the clinical setting, and its occurrence is influenced by various factors, particularly aging. Senescence of atrial myocytes plays an important role in the development of AF, although the precise mechanisms underlying this association remain unclear. This review explores the pivotal role of atrial myocyte senescence in AF pathogenesis, moving beyond chronological age. It provides evidence that aging creates a pro-arrhythmic substrate via three interconnected mechanisms: 1) inflammatory activation (mitochondrial ROS, NLRP3, and SASP), 2) dysregulated calcium handling (RyR2 and SERCA2), and 3) cell cycle disruption (p16, p21, and p53). These pathways, compounded by epigenetic changes and SIRT1/mTOR signaling dysregulation, drive the electrical and structural remodeling that triggers and sustains AF. The review highlights promising therapeutic targets such as SIRT1 activators and NLRP3 inhibitors, proposing an integrated “senescence–AF axis” model, while identifying key research gaps in cell-type specificity and clinical translation. This comprehensive review outlines current progress in research in this area and future research directions and provides valuable references for forthcoming studies.

## Linked entities

- **Genes:** RYR2 (ryanodine receptor 2) [NCBI Gene 6262], ATP2A2 (ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2) [NCBI Gene 488], CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029], CDKN1A (cyclin dependent kinase inhibitor 1A) [NCBI Gene 1026], TP53 (tumor protein p53) [NCBI Gene 7157], NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548], SIRT1 (sirtuin 1) [NCBI Gene 23411], MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475]
- **Diseases:** atrial fibrillation (MONDO:0004981)

## Full-text entities

- **Genes:** MTOR (mechanistic target of rapamycin kinase) [NCBI Gene 2475] {aka FRAP, FRAP1, FRAP2, RAFT1, RAPT1, SKS}, SIRT1 (sirtuin 1) [NCBI Gene 23411] {aka SIR2, SIR2L1, SIR2alpha}, RYR2 (ryanodine receptor 2) [NCBI Gene 6262] {aka ARVC2, ARVD2, RYR-2, RyR, VACRDS, VTSIP}, ATP2A2 (ATPase sarcoplasmic/endoplasmic reticulum Ca2+ transporting 2) [NCBI Gene 488] {aka ATP2B, DAR, DD, RHABDO2, SERCA2}, H3P16 (H3 histone pseudogene 16) [NCBI Gene 644914] {aka H3.6, H3F3AP6, p21}, CDKN2A (cyclin dependent kinase inhibitor 2A) [NCBI Gene 1029] {aka ARF, CAI2, CDK4I, CDKN2, CMM2, INK4}, TP53 (tumor protein p53) [NCBI Gene 7157] {aka BCC7, BMFS5, LFS1, P53, TRP53}, NLRP3 (NLR family pyrin domain containing 3) [NCBI Gene 114548] {aka AGTAVPRL, AII, AVP, C1orf7, CIAS1, CLR1.1}
- **Diseases:** AF (MESH:D001281), arrhythmia (MESH:D001145), inflammatory (MESH:D007249), arrhythmic (OMIM:212500)
- **Chemicals:** calcium (MESH:D002118), ROS (-)

## Full text

_Full body text omitted from this summary view._ Fetch the complete paper as Markdown: https://tomesphere.com/paper/PMC12846991/full.md

## Figures

5 figures with captions in the complete paper: https://tomesphere.com/paper/PMC12846991/full.md

## References

246 references — full list in the complete paper: https://tomesphere.com/paper/PMC12846991/full.md

---
Source: https://tomesphere.com/paper/PMC12846991